公开(公告)号：US10174126B2

公开(公告)日：2019-01-08

申请号：US15073231

申请日：2016-03-17

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Qi Zeng

IPC: C07K16/40 ,  A61K39/395 ,  C07K16/18 ,  G01N33/574 ,  C07K16/30 ,  A61K39/00

Abstract: We provide an antibody capable of binding to an intracellular PRL-I or PRL-3 polypeptide, in which the antibody is capable of binding to an epitope bound by antibody 269, antibody 223 or antibody 318. Such anti-PRL antibodies may be capable of binding to intracellular PRL-I or PRL-3. They may be suitable for use as therapies against cancer or metastasis thereof, or in clinical diagnosis to identify PRL-3 or PRL-1 positive patients.

公开(公告)号：US20140286937A1

公开(公告)日：2014-09-25

申请号：US14218288

申请日：2014-03-18

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Qi Zeng

IPC: C07K16/40 ,  G01N33/574 ,  A61K39/395

CPC classification number: C07K16/40 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  G01N33/57496 ,  G01N2333/916

Abstract: We provide an antibody capable of binding to an intracellular PRL-I or PRL-3 polypeptide, in which the antibody is capable of binding to an epitope bound by antibody 269, antibody 223 or antibody 318. Such anti-PRL antibodies may be capable of binding to intracellular PRL-I or PRL-3. They may be suitable for use as therapies against cancer or metastasis thereof, or in clinical diagnosis to identify PRL-3 or PRL-I positive patients.

Abstract translation: 我们提供能够结合细胞内PRL-1或PRL-3多肽的抗体，其中抗体能够结合抗体269，抗体223或抗体318结合的表位。这种抗PRL抗体可能能够 结合细胞内PRL-1或PRL-3。 它们可能适合用作抗癌或转移疗法，或临床诊断以鉴别PRL-3或PRL-1阳性患者。

公开(公告)号：US20140242092A1

公开(公告)日：2014-08-28

申请号：US14276203

申请日：2014-05-13

Applicant: Agency For Science, Technology And Research (A*STAR)

Inventor： Qi Zeng

IPC: C12N15/113 ,  G01N33/574 ,  C12Q1/44 ,  C07K16/40

CPC classification number: C12N15/1137 ,  C07K16/40 ,  C12N9/1205 ,  C12N9/16 ,  C12Q1/42 ,  C12Q1/44 ,  G01N33/57415 ,  G01N2333/916 ,  G01N2800/52 ,  G01N2800/56

Abstract: We provide VHZ for use in a method of treatment, prophylaxis or alleviation of a cancer, such as breast cancer, in an individual. We provide an anti-VHZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility of the individual to breast cancer comprising means for detection of VHZ expression in the individual or a sample taken from him or her as well as a method of detecting a cancer cell, the method comprising detecting modulation of expression, amount or activity of VHZ in the cell.

Abstract translation: 我们提供VHZ用于个体治疗，预防或缓解癌症如乳腺癌的方法。 我们提供用于治疗，预防或减轻癌症的抗VHZ药物。 我们进一步提供用于检测个体乳腺癌或个体对乳腺癌的易感性的试剂盒，其包括用于检测个体中VHZ表达的手段或取自他或她的样品以及检测癌细胞的方法 方法包括检测细胞中VHZ的表达，量或活性的调节。

公开(公告)号：US11155636B2

公开(公告)日：2021-10-26

申请号：US16309439

申请日：2017-06-14

Applicant: Agency for Science, Technology and Research

Inventor： Qi Zeng

IPC: C07K16/40 ,  A61P35/04 ,  C07K16/30 ,  A61K39/00

Abstract: The present invention relates to humanised antibodies that bind PRL3.

公开(公告)号：US09790503B2

公开(公告)日：2017-10-17

申请号：US14276203

申请日：2014-05-13

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)

Inventor： Qi Zeng

IPC: A61K39/00 ,  C07K16/30 ,  C12N15/113 ,  C07K16/40 ,  C12N9/12 ,  C12N9/16 ,  C12Q1/42 ,  G01N33/574 ,  C12Q1/44

CPC classification number: C12N15/1137 ,  C07K16/40 ,  C12N9/1205 ,  C12N9/16 ,  C12Q1/42 ,  C12Q1/44 ,  G01N33/57415 ,  G01N2333/916 ,  G01N2800/52 ,  G01N2800/56

Abstract: We provide VHZ for use in a method of treatment, prophylaxis or alleviation of a cancer, such as breast cancer, in an individual. We provide an anti-VHZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility of the individual to breast cancer comprising means for detection of VHZ expression in the individual or a sample taken from him or her as well as a method of detecting a cancer cell, the method comprising detecting modulation of expression, amount or activity of VHZ in the cell.

公开(公告)号：US20170234880A1

公开(公告)日：2017-08-17

申请号：US15503155

申请日：2015-08-13

Applicant: Agency for Science, Technology and Research

Inventor： Qi Zeng

IPC: G01N33/574 ,  C07K16/40

CPC classification number: G01N33/5748 ,  A61K2039/505 ,  C07K16/40 ,  C12Y301/03048 ,  G01N33/57488 ,  G01N2333/82 ,  G01N2333/916

Abstract: The data provided herewith show that, biomarkers found within the cells of a tumor or cancer may also be present at adequate levels within the patient's urine to enable detection. Method of diagnosis, patient selection and treatment are provided, along with kits and devices.

公开(公告)号：US20170008972A1

公开(公告)日：2017-01-12

申请号：US15073231

申请日：2016-03-17

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Qi Zeng

IPC: C07K16/40

CPC classification number: C07K16/40 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  G01N33/57496 ,  G01N2333/916

Abstract: We provide an antibody capable of binding to an intracellular PRL-I or PRL-3 polypeptide, in which the antibody is capable of binding to an epitope bound by antibody 269, antibody 223 or antibody 318. Such anti-PRL antibodies may be capable of binding to intracellular PRL-I or PRL-3. They may be suitable for use as therapies against cancer or metastasis thereof, or in clinical diagnosis to identify PRL-3 or PRL-1 positive patients.

Abstract translation: 我们提供能够结合细胞内PRL-1或PRL-3多肽的抗体，其中抗体能够结合抗体269，抗体223或抗体318结合的表位。这种抗PRL抗体可能能够 结合细胞内PRL-1或PRL-3。 它们可能适合用作抗癌或转移的治疗方法，或用于鉴定PRL-3或PRL-1阳性患者的临床诊断。

公开(公告)号：US09321845B2

公开(公告)日：2016-04-26

申请号：US14218288

申请日：2014-03-18

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Qi Zeng

IPC: A61K39/395 ,  C07K16/40 ,  C07K16/18 ,  G01N33/574 ,  A61K39/00

CPC classification number: C07K16/40 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  G01N33/57496 ,  G01N2333/916

Abstract: We provide an antibody capable of binding to an intracellular PRL-I or PRL-3 polypeptide, in which the antibody is capable of binding to an epitope bound by antibody 269, antibody 223 or antibody 318. Such anti-PRL antibodies may be capable of binding to intracellular PRL-I or PRL-3. They may be suitable for use as therapies against cancer or metastasis thereof, or in clinical diagnosis to identify PRL-3 or PRL-I positive patients.

Abstract translation: 我们提供能够结合细胞内PRL-1或PRL-3多肽的抗体，其中抗体能够结合抗体269，抗体223或抗体318结合的表位。这种抗PRL抗体可能能够 结合细胞内PRL-1或PRL-3。 它们可能适合用作抗癌或转移疗法，或临床诊断以鉴别PRL-3或PRL-1阳性患者。

公开(公告)号：US20170146538A1

公开(公告)日：2017-05-25

申请号：US15116956

申请日：2014-02-07

Applicant: Agency for Science, Technology and Research

Inventor： Qi Zeng

IPC: G01N33/574 ,  C07K16/30

CPC classification number: G01N33/57426 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/3061 ,  C07K16/40 ,  C07K2317/76 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N2333/912 ,  G01N2333/916 ,  G01N2800/52

Abstract: Previously, we have shown that a cancer associated-PRL-3 intracellular phosphatase is a potential therapeutic target for PRL-3 antibody therapy. PRL-3 has recently emerged as a potentially useful biomarker for cancer prognosis, particularly the prediction of cancer metastasis (Matsukawa et al, 2010, Ren et al, 12 2009). Here we demonstrate that PRL-3 can act as an independent prognostic marker for cancers.